XERS
Xeris Biopharma Holdings, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 94 | +4 | 81.60M | $645.79M | +9 | −4 |
| Q1 2026 | 92 | +4 | 77.44M | $449.36M | +7 | −4 |
| Q4 2025 | 88 | +2 | 77.86M | $611.14M | +3 | — |
| Q3 2025 | 17 | 0 | 48.63M | $395.88M | +1 | −2 |
| Q2 2025 | 15 | -1 | 41.39M | $193.31M | — | −1 |
| Q1 2025 | 13 | +3 | 18.95M | $104.02M | +4 | −1 |
| Q4 2024 | 10 | +1 | 14.55M | $49.32M | +1 | — |
| Q3 2024 | 8 | -1 | 9.23M | $26.32M | — | −1 |
| Q2 2024 | 9 | — | 8.75M | $19.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 3.24M | — | $7.29M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 1.70M | — | $3.82M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 1.35M | — | $3.04M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 1.19M | — | $2.68M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | D. E. Shaw & Co. ✦ | 518.02K | — | $1.17M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 422.11K | — | $949,746 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Fairfax Financial ✦ | 170.94K | — | $382,899 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 130.97K | — | $295,000 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 26.80K | — | $60,307 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 229 holders, 93.59M shares, $532.36M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 25.00K sh · $250,000
Officer · 16.67K sh · $141,434
Officer · 15.00K sh · $127,308
Officer · 5.00K sh · $42,500
Officer · 5.00K sh · $42,500
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology